"10.1371_journal.pmed.1000431","plos medicine","2011-04-05T00:00:00Z","Aaron S Kesselheim; Michelle M Mello; David M Studdert","Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Womens Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America; School of Law, University of Melbourne, Melbourne, Australia; School of Population Health, University of Melbourne, Melbourne, Australia","ICMJE criteria for authorship read and met: ASK MMM DMS. Agree with the manuscripts results and conclusions: ASK MMM DMS. Designed the experiments/the study: ASK DMS. Analyzed the data: ASK DMS. Collected data/did experiments for the study: ASK DMS. Wrote the first draft of the paper: ASK. Contributed to the writing of the paper: ASK MMM DMS. Contributed to the design of the study: MMM.","ASK reports consulting for the Alosa Foundation, a nonprofit organization that runs the Independent Drug Information Service and is not affiliated in any way with any pharmaceutical company. From 2008â€2009, ASK served as an expert witness for the state of Texas in a lawsuit against Merck related to improper promotion of rofecoxib (Vioxx). From 2007â€2008, ASK helped develop an educational program to encourage evidence-based prescribing, with funding from a grant derived from the settlement of a fraud case regarding improper promotion of gabapentin (Neurontin).","2011","04","Aaron S Kesselheim","ASK",3,TRUE,NA,NA,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
